| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Leukemia, Myeloid, Acute | 10 | 2019 | 776 | 1.410 |
Why?
|
| Hematopoietic Stem Cell Transplantation | 16 | 2023 | 879 | 1.400 |
Why?
|
| Programmed Cell Death 1 Receptor | 7 | 2023 | 164 | 1.340 |
Why?
|
| Immunotherapy | 8 | 2023 | 648 | 1.330 |
Why?
|
| T-Lymphocytes, Regulatory | 4 | 2016 | 298 | 1.110 |
Why?
|
| Immune Tolerance | 5 | 2017 | 338 | 1.080 |
Why?
|
| T-Lymphocytes | 11 | 2021 | 1205 | 1.060 |
Why?
|
| Antibodies, Monoclonal | 7 | 2023 | 1393 | 0.950 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 3 | 2021 | 153 | 0.950 |
Why?
|
| Transplantation Conditioning | 13 | 2020 | 371 | 0.940 |
Why?
|
| B7-H1 Antigen | 6 | 2020 | 264 | 0.930 |
Why?
|
| Lymphoma | 4 | 2020 | 264 | 0.910 |
Why?
|
| Hodgkin Disease | 2 | 2017 | 179 | 0.870 |
Why?
|
| Immunotherapy, Adoptive | 3 | 2021 | 184 | 0.820 |
Why?
|
| Melanoma, Experimental | 3 | 2014 | 103 | 0.810 |
Why?
|
| Tumor Escape | 2 | 2020 | 51 | 0.790 |
Why?
|
| Antigen-Presenting Cells | 3 | 2017 | 139 | 0.780 |
Why?
|
| Graft vs Host Disease | 9 | 2020 | 357 | 0.770 |
Why?
|
| Leukemia | 4 | 2017 | 321 | 0.730 |
Why?
|
| Antineoplastic Agents | 10 | 2023 | 2384 | 0.690 |
Why?
|
| Homeostasis | 3 | 2012 | 406 | 0.680 |
Why?
|
| Cell Proliferation | 5 | 2016 | 1621 | 0.680 |
Why?
|
| Lymphoma, B-Cell | 1 | 2020 | 104 | 0.670 |
Why?
|
| Neoplasms | 8 | 2018 | 2970 | 0.650 |
Why?
|
| Arabinonucleosides | 3 | 2011 | 39 | 0.640 |
Why?
|
| Immune Evasion | 1 | 2017 | 33 | 0.590 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 7 | 2023 | 2508 | 0.580 |
Why?
|
| Transplantation, Homologous | 16 | 2020 | 994 | 0.550 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2013 | 261 | 0.520 |
Why?
|
| Immunity, Innate | 3 | 2016 | 424 | 0.520 |
Why?
|
| Lymphocyte Activation | 4 | 2016 | 737 | 0.520 |
Why?
|
| Hematologic Neoplasms | 5 | 2023 | 334 | 0.500 |
Why?
|
| Lymphocyte Depletion | 4 | 2017 | 97 | 0.480 |
Why?
|
| Thymus Gland | 1 | 2014 | 196 | 0.460 |
Why?
|
| CD40 Antigens | 1 | 2013 | 43 | 0.450 |
Why?
|
| Tumor Microenvironment | 4 | 2023 | 440 | 0.440 |
Why?
|
| Signal Transduction | 5 | 2017 | 3327 | 0.430 |
Why?
|
| Geriatric Assessment | 4 | 2020 | 180 | 0.430 |
Why?
|
| Cross-Priming | 1 | 2012 | 48 | 0.410 |
Why?
|
| Graft vs Tumor Effect | 2 | 2010 | 25 | 0.400 |
Why?
|
| Animals | 21 | 2020 | 26951 | 0.390 |
Why?
|
| B7-1 Antigen | 3 | 2016 | 76 | 0.390 |
Why?
|
| Mice, Inbred C57BL | 9 | 2016 | 3161 | 0.390 |
Why?
|
| Antigen Presentation | 3 | 2020 | 211 | 0.390 |
Why?
|
| Adenine Nucleotides | 2 | 2011 | 63 | 0.370 |
Why?
|
| Humans | 47 | 2023 | 87555 | 0.360 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 2010 | 112 | 0.360 |
Why?
|
| Cord Blood Stem Cell Transplantation | 4 | 2017 | 89 | 0.360 |
Why?
|
| Antibodies, Neoplasm | 2 | 2009 | 84 | 0.350 |
Why?
|
| Membrane Proteins | 1 | 2016 | 1210 | 0.350 |
Why?
|
| Cell Differentiation | 3 | 2016 | 1501 | 0.340 |
Why?
|
| WT1 Proteins | 1 | 2009 | 19 | 0.340 |
Why?
|
| CD8-Positive T-Lymphocytes | 5 | 2016 | 582 | 0.340 |
Why?
|
| Salvage Therapy | 1 | 2010 | 234 | 0.340 |
Why?
|
| Rituximab | 4 | 2023 | 117 | 0.330 |
Why?
|
| Antigens, Differentiation | 1 | 2009 | 141 | 0.330 |
Why?
|
| Cytotoxicity, Immunologic | 1 | 2009 | 212 | 0.330 |
Why?
|
| Mice | 14 | 2016 | 11586 | 0.330 |
Why?
|
| Mice, Knockout | 7 | 2016 | 1967 | 0.300 |
Why?
|
| Membrane Glycoproteins | 1 | 2009 | 430 | 0.290 |
Why?
|
| Leukemia, T-Cell | 1 | 2006 | 17 | 0.290 |
Why?
|
| Ganciclovir | 1 | 2006 | 49 | 0.270 |
Why?
|
| Flow Cytometry | 4 | 2013 | 686 | 0.270 |
Why?
|
| Valine | 1 | 2006 | 62 | 0.270 |
Why?
|
| CD47 Antigen | 2 | 2016 | 23 | 0.270 |
Why?
|
| Acyclovir | 1 | 2006 | 107 | 0.260 |
Why?
|
| Peptides | 1 | 2009 | 644 | 0.260 |
Why?
|
| Antiviral Agents | 2 | 2007 | 513 | 0.260 |
Why?
|
| Cytomegalovirus Infections | 1 | 2006 | 145 | 0.250 |
Why?
|
| Bone Marrow Transplantation | 1 | 2006 | 283 | 0.250 |
Why?
|
| Middle Aged | 23 | 2019 | 25343 | 0.250 |
Why?
|
| Aged | 22 | 2020 | 18644 | 0.240 |
Why?
|
| Transplantation, Autologous | 4 | 2020 | 340 | 0.240 |
Why?
|
| Survival Analysis | 6 | 2017 | 1535 | 0.230 |
Why?
|
| Interferon Type I | 2 | 2016 | 176 | 0.220 |
Why?
|
| Lymphoma, Follicular | 1 | 2023 | 72 | 0.220 |
Why?
|
| Male | 25 | 2020 | 41502 | 0.220 |
Why?
|
| Self Tolerance | 2 | 2016 | 24 | 0.210 |
Why?
|
| Cell Separation | 2 | 2013 | 195 | 0.210 |
Why?
|
| Antigens, Neoplasm | 2 | 2016 | 330 | 0.210 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 2 | 2013 | 77 | 0.200 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 2 | 2012 | 64 | 0.200 |
Why?
|
| Histiocytes | 1 | 2021 | 22 | 0.200 |
Why?
|
| Cell Line, Tumor | 5 | 2016 | 2500 | 0.200 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2005 | 393 | 0.200 |
Why?
|
| Antigens, CD19 | 1 | 2021 | 41 | 0.200 |
Why?
|
| Adult | 18 | 2019 | 26018 | 0.200 |
Why?
|
| Cell- and Tissue-Based Therapy | 1 | 2021 | 49 | 0.190 |
Why?
|
| Disease Models, Animal | 3 | 2016 | 2300 | 0.190 |
Why?
|
| Interferon-gamma | 3 | 2013 | 446 | 0.190 |
Why?
|
| Dendritic Cells | 2 | 2016 | 434 | 0.190 |
Why?
|
| Recurrence | 4 | 2017 | 1162 | 0.180 |
Why?
|
| Hepatitis A Virus Cellular Receptor 2 | 1 | 2019 | 5 | 0.180 |
Why?
|
| Galectins | 1 | 2019 | 8 | 0.170 |
Why?
|
| Guidelines as Topic | 1 | 2020 | 159 | 0.170 |
Why?
|
| Female | 23 | 2020 | 45191 | 0.170 |
Why?
|
| Hydrazines | 1 | 2019 | 30 | 0.170 |
Why?
|
| Mitoxantrone | 1 | 2019 | 68 | 0.170 |
Why?
|
| Myelodysplastic Syndromes | 2 | 2017 | 349 | 0.170 |
Why?
|
| Fetal Blood | 2 | 2017 | 89 | 0.170 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2020 | 1232 | 0.170 |
Why?
|
| Clinical Trials as Topic | 3 | 2010 | 1138 | 0.170 |
Why?
|
| Interdisciplinary Communication | 1 | 2019 | 130 | 0.170 |
Why?
|
| Triazoles | 1 | 2019 | 98 | 0.160 |
Why?
|
| Cytarabine | 1 | 2019 | 219 | 0.160 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2023 | 1343 | 0.160 |
Why?
|
| Proto-Oncogene Proteins c-myc | 1 | 2019 | 125 | 0.160 |
Why?
|
| Melphalan | 2 | 2023 | 98 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 2019 | 190 | 0.150 |
Why?
|
| Treatment Outcome | 8 | 2019 | 8054 | 0.150 |
Why?
|
| Clonal Anergy | 2 | 2008 | 31 | 0.150 |
Why?
|
| Receptors, Pattern Recognition | 1 | 2017 | 19 | 0.150 |
Why?
|
| Remission Induction | 2 | 2017 | 730 | 0.150 |
Why?
|
| Disease Management | 1 | 2019 | 321 | 0.150 |
Why?
|
| Preoperative Care | 1 | 2019 | 399 | 0.150 |
Why?
|
| Patient Care Team | 1 | 2019 | 280 | 0.150 |
Why?
|
| Gene Expression Regulation, Leukemic | 2 | 2015 | 91 | 0.140 |
Why?
|
| Drug Therapy, Combination | 2 | 2010 | 794 | 0.140 |
Why?
|
| Health Services Misuse | 1 | 2016 | 19 | 0.140 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2017 | 139 | 0.140 |
Why?
|
| Multiple Myeloma | 1 | 2020 | 318 | 0.140 |
Why?
|
| Xanthones | 1 | 2016 | 11 | 0.140 |
Why?
|
| Receptors, Antigen, T-Cell | 4 | 2016 | 382 | 0.140 |
Why?
|
| Paramyxoviridae | 1 | 2015 | 10 | 0.140 |
Why?
|
| Haploidy | 1 | 2016 | 32 | 0.140 |
Why?
|
| Basic-Leucine Zipper Transcription Factors | 1 | 2016 | 43 | 0.140 |
Why?
|
| Genetic Engineering | 1 | 2016 | 115 | 0.130 |
Why?
|
| Community-Acquired Infections | 1 | 2015 | 63 | 0.130 |
Why?
|
| Immunity | 1 | 2016 | 138 | 0.130 |
Why?
|
| Lymphocyte Subsets | 2 | 2013 | 64 | 0.130 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2015 | 102 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Humanized | 3 | 2011 | 942 | 0.130 |
Why?
|
| Immunologic Memory | 1 | 2016 | 161 | 0.130 |
Why?
|
| Respiratory Tract Infections | 1 | 2015 | 107 | 0.130 |
Why?
|
| Adaptive Immunity | 1 | 2016 | 167 | 0.130 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 1 | 2015 | 130 | 0.130 |
Why?
|
| Receptor, Interferon alpha-beta | 1 | 2014 | 20 | 0.120 |
Why?
|
| Survival Rate | 4 | 2014 | 1870 | 0.120 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2013 | 378 | 0.120 |
Why?
|
| Antigens, CD34 | 4 | 2017 | 158 | 0.120 |
Why?
|
| Mice, Transgenic | 3 | 2013 | 1563 | 0.120 |
Why?
|
| Inflammation | 1 | 2020 | 948 | 0.120 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 2 | 2012 | 50 | 0.120 |
Why?
|
| Toll-Like Receptor 9 | 1 | 2013 | 20 | 0.120 |
Why?
|
| Gene Expression Regulation | 2 | 2017 | 1956 | 0.120 |
Why?
|
| Interferon-beta | 1 | 2014 | 125 | 0.120 |
Why?
|
| Haplotypes | 2 | 2013 | 637 | 0.120 |
Why?
|
| Young Adult | 7 | 2017 | 6117 | 0.120 |
Why?
|
| Interleukin-18 | 1 | 2013 | 26 | 0.110 |
Why?
|
| STAT3 Transcription Factor | 1 | 2013 | 81 | 0.110 |
Why?
|
| Alemtuzumab | 3 | 2011 | 84 | 0.110 |
Why?
|
| Glucocorticoids | 1 | 2015 | 355 | 0.110 |
Why?
|
| Lymphoma, T-Cell, Peripheral | 1 | 2013 | 29 | 0.110 |
Why?
|
| Molecular Targeted Therapy | 1 | 2015 | 278 | 0.110 |
Why?
|
| Transplantation, Haploidentical | 3 | 2017 | 27 | 0.110 |
Why?
|
| Intensive Care Units | 1 | 2016 | 380 | 0.110 |
Why?
|
| Epothilones | 1 | 2013 | 13 | 0.110 |
Why?
|
| Repressor Proteins | 1 | 2016 | 415 | 0.110 |
Why?
|
| Prostate | 1 | 2016 | 391 | 0.110 |
Why?
|
| Combined Modality Therapy | 3 | 2010 | 1695 | 0.100 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2019 | 608 | 0.100 |
Why?
|
| Tumor Cells, Cultured | 2 | 2015 | 1048 | 0.100 |
Why?
|
| Neovascularization, Pathologic | 1 | 2014 | 364 | 0.100 |
Why?
|
| Hematopoiesis | 1 | 2013 | 164 | 0.100 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2014 | 312 | 0.100 |
Why?
|
| Translocation, Genetic | 2 | 2019 | 266 | 0.100 |
Why?
|
| Tissue Donors | 2 | 2012 | 486 | 0.100 |
Why?
|
| Cell Movement | 2 | 2016 | 779 | 0.100 |
Why?
|
| Aged, 80 and over | 6 | 2019 | 6613 | 0.100 |
Why?
|
| Graft Survival | 2 | 2013 | 902 | 0.100 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2015 | 597 | 0.100 |
Why?
|
| Leukocyte Transfusion | 1 | 2010 | 15 | 0.100 |
Why?
|
| Hospitalization | 1 | 2016 | 858 | 0.090 |
Why?
|
| Cell Survival | 1 | 2013 | 977 | 0.090 |
Why?
|
| Incidence | 3 | 2015 | 1569 | 0.090 |
Why?
|
| Immunomodulation | 1 | 2010 | 55 | 0.090 |
Why?
|
| Graft Rejection | 1 | 2016 | 1072 | 0.090 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2010 | 200 | 0.090 |
Why?
|
| Interleukin-2 | 1 | 2010 | 250 | 0.090 |
Why?
|
| Stem Cell Transplantation | 2 | 2020 | 185 | 0.080 |
Why?
|
| Antigens, CD | 1 | 2010 | 462 | 0.080 |
Why?
|
| Neoplasm Transplantation | 1 | 2009 | 396 | 0.080 |
Why?
|
| Chimerism | 2 | 2020 | 36 | 0.080 |
Why?
|
| Neoplasm Staging | 2 | 2010 | 1962 | 0.080 |
Why?
|
| Cells, Cultured | 1 | 2013 | 2842 | 0.080 |
Why?
|
| Immunosuppressive Agents | 2 | 2015 | 984 | 0.080 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2009 | 172 | 0.080 |
Why?
|
| Acute Kidney Injury | 1 | 2011 | 302 | 0.080 |
Why?
|
| Down-Regulation | 1 | 2009 | 512 | 0.080 |
Why?
|
| Melanoma | 1 | 2011 | 461 | 0.070 |
Why?
|
| Immunity, Cellular | 1 | 2007 | 178 | 0.070 |
Why?
|
| Cyclosporine | 1 | 2007 | 236 | 0.070 |
Why?
|
| Lymphopenia | 1 | 2006 | 30 | 0.070 |
Why?
|
| Models, Animal | 1 | 2007 | 270 | 0.070 |
Why?
|
| Time Factors | 2 | 2013 | 5262 | 0.070 |
Why?
|
| Autoimmune Diseases | 1 | 2007 | 244 | 0.070 |
Why?
|
| Protein Binding | 1 | 2009 | 1475 | 0.060 |
Why?
|
| Neoplasms, Experimental | 1 | 2006 | 269 | 0.060 |
Why?
|
| Disease Progression | 1 | 2009 | 1473 | 0.060 |
Why?
|
| Prognosis | 4 | 2018 | 3708 | 0.060 |
Why?
|
| Age Factors | 3 | 2015 | 1848 | 0.060 |
Why?
|
| Mutation | 1 | 2015 | 4061 | 0.060 |
Why?
|
| Pilot Projects | 2 | 2020 | 855 | 0.060 |
Why?
|
| RNA, Small Interfering | 2 | 2015 | 554 | 0.050 |
Why?
|
| Histocompatibility Testing | 2 | 2017 | 138 | 0.050 |
Why?
|
| Adolescent | 3 | 2016 | 9080 | 0.050 |
Why?
|
| Risk Factors | 3 | 2018 | 5373 | 0.050 |
Why?
|
| Illinois | 2 | 2012 | 464 | 0.050 |
Why?
|
| Health Planning Guidelines | 1 | 2019 | 22 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2006 | 1412 | 0.040 |
Why?
|
| Health Plan Implementation | 1 | 2019 | 56 | 0.040 |
Why?
|
| Standard of Care | 1 | 2019 | 63 | 0.040 |
Why?
|
| Vincristine | 1 | 2019 | 112 | 0.040 |
Why?
|
| Treatment Failure | 1 | 2019 | 288 | 0.040 |
Why?
|
| Maintenance Chemotherapy | 1 | 2019 | 76 | 0.040 |
Why?
|
| Prospective Studies | 2 | 2020 | 4232 | 0.040 |
Why?
|
| Disease-Free Survival | 2 | 2012 | 1208 | 0.040 |
Why?
|
| Etoposide | 1 | 2019 | 197 | 0.040 |
Why?
|
| Prednisone | 1 | 2019 | 258 | 0.040 |
Why?
|
| Preoperative Period | 1 | 2018 | 91 | 0.040 |
Why?
|
| Bone Marrow Cells | 1 | 2019 | 257 | 0.040 |
Why?
|
| Cyclophosphamide | 1 | 2019 | 300 | 0.040 |
Why?
|
| Maximum Tolerated Dose | 1 | 2019 | 271 | 0.040 |
Why?
|
| Doxorubicin | 1 | 2019 | 297 | 0.040 |
Why?
|
| Premedication | 1 | 2017 | 55 | 0.040 |
Why?
|
| Unrelated Donors | 1 | 2017 | 44 | 0.040 |
Why?
|
| Palliative Care | 1 | 2019 | 262 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2019 | 273 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2019 | 267 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 269 | 0.040 |
Why?
|
| Drug Administration Schedule | 1 | 2019 | 900 | 0.040 |
Why?
|
| Feasibility Studies | 1 | 2019 | 766 | 0.040 |
Why?
|
| Receptors, CCR7 | 1 | 2016 | 16 | 0.030 |
Why?
|
| B7-2 Antigen | 1 | 2016 | 40 | 0.030 |
Why?
|
| CD8 Antigens | 1 | 2016 | 81 | 0.030 |
Why?
|
| Histocompatibility | 1 | 2016 | 66 | 0.030 |
Why?
|
| Multiplex Polymerase Chain Reaction | 1 | 2015 | 33 | 0.030 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2018 | 856 | 0.030 |
Why?
|
| U937 Cells | 1 | 2015 | 32 | 0.030 |
Why?
|
| Patient Selection | 1 | 2019 | 682 | 0.030 |
Why?
|
| Terminal Care | 1 | 2016 | 133 | 0.030 |
Why?
|
| Comorbidity | 1 | 2018 | 933 | 0.030 |
Why?
|
| Transplant Recipients | 1 | 2015 | 133 | 0.030 |
Why?
|
| Prevalence | 1 | 2018 | 1246 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2015 | 465 | 0.030 |
Why?
|
| Boronic Acids | 1 | 2013 | 55 | 0.030 |
Why?
|
| Bortezomib | 1 | 2013 | 81 | 0.030 |
Why?
|
| Mice, Inbred NOD | 1 | 2013 | 190 | 0.030 |
Why?
|
| Immunoglobulin Isotypes | 1 | 2013 | 31 | 0.030 |
Why?
|
| Pneumococcal Vaccines | 1 | 2013 | 27 | 0.030 |
Why?
|
| CpG Islands | 1 | 2013 | 155 | 0.030 |
Why?
|
| Mice, SCID | 1 | 2013 | 261 | 0.030 |
Why?
|
| Gene Silencing | 1 | 2013 | 175 | 0.030 |
Why?
|
| Lymphocyte Count | 1 | 2013 | 94 | 0.030 |
Why?
|
| Mice, Inbred BALB C | 1 | 2015 | 1073 | 0.030 |
Why?
|
| Pyrazines | 1 | 2013 | 92 | 0.030 |
Why?
|
| Killer Cells, Natural | 1 | 2014 | 271 | 0.030 |
Why?
|
| Virus Diseases | 1 | 2013 | 96 | 0.030 |
Why?
|
| Deoxycytidine | 1 | 2013 | 237 | 0.030 |
Why?
|
| Adult Stem Cells | 1 | 2011 | 29 | 0.030 |
Why?
|
| STAT1 Transcription Factor | 1 | 2011 | 52 | 0.030 |
Why?
|
| L-Lactate Dehydrogenase | 1 | 2010 | 70 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2011 | 276 | 0.020 |
Why?
|
| Family | 1 | 2012 | 316 | 0.020 |
Why?
|
| Risk | 1 | 2011 | 660 | 0.020 |
Why?
|
| B-Lymphocytes | 1 | 2014 | 730 | 0.020 |
Why?
|
| Lymphatic Metastasis | 1 | 2011 | 498 | 0.020 |
Why?
|
| DNA | 1 | 2015 | 1305 | 0.020 |
Why?
|
| Predictive Value of Tests | 1 | 2014 | 1687 | 0.020 |
Why?
|
| Transcription Factors | 1 | 2016 | 1619 | 0.020 |
Why?
|
| Lymph Nodes | 1 | 2011 | 546 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2014 | 2791 | 0.020 |
Why?
|
| Genes, RAG-1 | 1 | 2006 | 13 | 0.020 |
Why?
|
| Lewis X Antigen | 1 | 2006 | 9 | 0.020 |
Why?
|
| Myeloid Progenitor Cells | 1 | 2006 | 16 | 0.020 |
Why?
|
| Expressed Sequence Tags | 1 | 2006 | 35 | 0.020 |
Why?
|
| Adoptive Transfer | 1 | 2006 | 169 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2006 | 106 | 0.020 |
Why?
|
| Chromosomes, Human, Pair 9 | 1 | 2006 | 86 | 0.020 |
Why?
|
| Gene Library | 1 | 2006 | 132 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2006 | 394 | 0.020 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 202 | 0.020 |
Why?
|
| Cost of Illness | 1 | 2005 | 147 | 0.020 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2006 | 696 | 0.010 |
Why?
|
| Cytokines | 1 | 2006 | 794 | 0.010 |
Why?
|
| Computational Biology | 1 | 2006 | 534 | 0.010 |
Why?
|
| Neoplasm Metastasis | 1 | 2006 | 1092 | 0.010 |
Why?
|
| RNA | 1 | 2006 | 571 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2006 | 1994 | 0.010 |
Why?
|
| Apoptosis | 1 | 2006 | 1703 | 0.010 |
Why?
|